Hepatitis C Virus | Pharmacor | G7 | 2015

Last Updated 8 December 2015
The hepatitis C virus (HCV) therapy market is undergoing unprecedented growth. Commercial opportunity is driven by a large prevalent population and historically high unmet medical need due to the suboptimal efficacy and tolerability of interferon-based therapies. Between 2013 and 2015, several direct-acting antivirals (DAAs) and DAA combinations, including simeprevir (Janssen’s Olysio, Medivir’s Sovriad), sofosbuvir (Gilead’s Sovaldi), sofosbuvir/ledipasvir (Gilead’s Harvoni), ombitasvir/paritaprevir/ritonavir plus dasabuvir (AbbVie’s Viekira Pak), and daclatasvir (Bristol-Myers Squibb’s Daklinza), have launched in the G7 for both treatment-naive and -experienced HCV patients. Despite these agents’ high prices, they have become a new standard of care.

Login to access report